USA - engelsk - NLM (National Library of Medicine)

the medicines company - oritavancin (unii: pug62frz2e) (oritavancin - unii:pug62frz2e) - oritavancin 400 mg - orbactiv ® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (absssi) caused by susceptible isolates of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-susceptible and methicillin–resistant isolates), streptococcus pyogenes , streptococcus agalactiae , streptococcus dysgalactiae , streptococcus anginosus group (includes s. anginosus , s. intermedius , and s. constellatus ), and enterococcus faecalis (vancomycin-susceptible isolates only). to reduce the development of drug-resistant bacteria and maintain the effectiveness of orbactiv and other antibacterial drugs, orbactiv should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are availabl

USA - engelsk - NLM (National Library of Medicine)

melinta therapeutics, llc - oritavancin (unii: pug62frz2e) (oritavancin - unii:pug62frz2e) - oritavancin 400 mg - orbactiv® (oritavancin) is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (absssi) caused by susceptible isolates of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), streptococcus pyogenes , streptococcus agalactiae , streptococcus dysgalactiae , streptococcus anginosus group (includes s. anginosus , s. intermedius , and s. constellatus ), and enterococcus faecalis (vancomycin-susceptible isolates only). to reduce the development of drug-resistant bacteria and maintain the effectiveness of orbactiv and other antibacterial drugs, orbactiv should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patt

Den europeiske union - dansk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibakterielle midler til systemisk brug, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Den europeiske union - maltesisk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibatteriċi għal użu sistemiku, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 u 5. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Den europeiske union - rumensk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibacteriene pentru uz sistemic, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 și 5. trebuie luate în considerare ghidurile oficiale referitoare la utilizarea adecvată a medicamentelor antibacteriene.

Den europeiske union - svensk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibakteriella medel för systemiskt bruk, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 och 5. hänsyn bör tas till officiella riktlinjer för lämplig användning av antibakteriella medel.

Den europeiske union - slovakisk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibakteriálne pre systémové použitie, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 a 5. je treba vziať do úvahy oficiálne usmernenie o vhodnom používaní antibakteriálne agentov.

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibakteriální látky pro systémové použití, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 a 5. pozornost by měla být věnována oficiálním doporučením pro správné používání antibakteriálních látek.

Den europeiske union - slovensk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibacterials za sistemsko uporabo, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 in 5. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Den europeiske union - litauisk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibacterials sisteminio naudojimo, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 ir 5. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.